Contact

All Stories

  1. Structural constraints link differences in neutralization potency of human anti-Eastern equine encephalitis virus monoclonal antibodies

    Article • Proceedings of the National Academy of Sciences, March 2023, Proceedings of the National Academy of Sciences

    Dr James E Crowe

  2. Epitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER region

    Article • PLoS Pathogens, May 2022, PLOS

    Dr James E Crowe

  3. Potent neutralization of Rift Valley fever virus by human monoclonal antibodies through fusion inhibition

    Article • Proceedings of the National Academy of Sciences, March 2021, Proceedings of the National Academy of Sciences

    Dr James E Crowe

  4. Antibody affinity versus dengue morphology influences neutralization

    Article • PLoS Pathogens, February 2021, PLOS

    Dr James E Crowe

  5. Diverse patterns of antibody variable gene repertoire disruption in patients with amyloid light chain (AL) amyloidosis

    Article • PLOS One, July 2020, PLOS

    Dr James E Crowe

  6. Human monoclonal antibodies against Ross River virus target epitopes within the E2 protein and protect against disease

    Article • PLoS Pathogens, May 2020, PLOS

    Dr James E Crowe

  7. Peptide arrays incubated with three collections of human sera from patients infected with mosquito-borne viruses

    Article • F1000Research, February 2020, Faculty of 1000, Ltd.

    Dr James E Crowe

  8. Peptide arrays of three collections of human sera from patients infected with mosquito-borne viruses

    Article • F1000Research, February 2020, Faculty of 1000, Ltd.

    Dr James E Crowe

  9. Multi-state design of flexible proteins predicts sequences optimal for conformational change

    Article • PLoS Computational Biology, February 2020, PLOS

    Dr James E Crowe

  10. Broad dengue neutralization in mosquitoes expressing an engineered antibody

    Article • PLoS Pathogens, January 2020, PLOS

    Dr James E Crowe

  11. Human-likeness of antibody biologics determined by back-translation and comparison with large antibody variable gene repertoires

    Article • mAbs, January 2020, Taylor & Francis

    Dr James E Crowe

  12. Immune repertoire fingerprinting by principal component analysis reveals shared features in subject groups with common exposures

    Article • BMC Bioinformatics, December 2019, Springer Science + Business Media

    Dr James E Crowe

  13. Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice

    Article • Cell Host & Microbe, December 2019, Elsevier

    Dr James E Crowe

  14. Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies

    Article • Cell Host & Microbe, December 2019, Elsevier

    Dr James E Crowe

  15. Mechanism of differential Zika and dengue virus neutralization by a public antibody lineage targeting the DIII lateral ridge

    Article • Journal of Experimental Medicine, November 2019, Rockefeller University Press

    Dr James E Crowe

  16. Peptide arrays of three collections of human sera from patients infected with mosquito-borne viruses

    Article • F1000Research, November 2019, Faculty of 1000, Ltd.

    Dr James E Crowe, Ivette Lorenzana

  17. Human VH1-69 Gene-Encoded Human Monoclonal Antibodies against Staphylococcus aureus IsdB Use at Least Three Distinct Modes of Binding To Inhibit Bacterial Growth and Pathogenesis

    Article • mBio, October 2019, ASM Journals

    Dr James E Crowe

  18. Harmonization of Zika neutralization assays by using the WHO International Standard for anti-Zika virus antibody

    Article • npj Vaccines, October 2019, Springer Science + Business Media

    Dr James E Crowe

  19. Mucosal Immunization with a pH-Responsive Nanoparticle Vaccine Induces Protective CD8+ Lung-Resident Memory T Cells

    Article • ACS Nano, October 2019, American Chemical Society (ACS)

    Dr James E Crowe

  20. Ehrlichia chaffeensis Outer Membrane Protein 1-Specific Human Antibody-Mediated Immunity Is Defined by Intracellular TRIM21-Dependent Innate Immune Activation and Extracellular Neutralization

    Article • Infection and Immunity, September 2019, ASM Journals

    Dr James E Crowe

  21. Multi-State Design of Flexible Proteins Predicts Sequences Optimal for Conformational Change

    Article • August 2019, Cold Spring Harbor Laboratory Press

    Dr James E Crowe

  22. Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance

    Article • Journal of Clinical Investigation, August 2019, American Society for Clinical Investigation

    Dr James E Crowe, Dr Stuart C. Ray

  23. Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopes

    Article • Vaccine, July 2019, Elsevier

    Dr James E Crowe

  24. New-Onset Post-Transplant Diabetes Mellitus after Allogeneic Hematopoietic Cell Transplant Is Initiated by Insulin Resistance, Not Immunosuppressive Medications

    Article • Biology of Blood and Marrow Transplantation, June 2019, Elsevier

    Dr James E Crowe

  25. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection

    Article • Science Immunology, May 2019, American Association for the Advancement of Science

    Dr James E Crowe

  26. Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2

    Article • Journal of Virology, May 2019, ASM Journals

    Dr James E Crowe

  27. A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface

    Article • Cell, May 2019, Elsevier

    Dr James E Crowe

  28. Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk

    Article • Nature Communications, April 2019, Springer Science + Business Media

    Dr James E Crowe

  29. Antibody Determinants of Influenza Immunity

    Article • The Journal of Infectious Diseases, April 2019, Oxford University Press (OUP)

    Dr James E Crowe

  30. Structural Diversity of Ultralong CDRH3s in Seven Bovine Antibody Heavy Chains

    Article • Frontiers in Immunology, March 2019, Frontiers

    Dr James E Crowe

  31. High frequency of shared clonotypes in human B cell receptor repertoires

    Article • Nature, February 2019, Springer Science + Business Media

    Dr James E Crowe

  32. Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection

    Article • Journal of Virology, February 2019, ASM Journals

    Dr James E Crowe

  33. Potent anti-influenza H7 human monoclonal antibody induces separation of hemagglutinin receptor-binding head domains

    Article • PLoS Biology, February 2019, PLOS

    Dr James E Crowe

  34. Dengue and Zika Virus Cross-Reactive Human Monoclonal Antibodies Protect against Spondweni Virus Infection and Pathogenesis in Mice

    Article • Cell Reports, February 2019, Elsevier

    Dr James E Crowe

  35. Mechanism of Enhanced Immature Dengue Virus Attachment to Endosomal Membrane Induced by prM Antibody

    Article • Structure, February 2019, Elsevier

    Dr James E Crowe

  36. Multistate design of influenza antibodies improves affinity and breadth against seasonal viruses

    Article • Proceedings of the National Academy of Sciences, January 2019, Proceedings of the National Academy of Sciences

    Dr James E Crowe

  37. Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope

    Article • Proceedings of the National Academy of Sciences, January 2019, Proceedings of the National Academy of Sciences

    Dr James E Crowe

  38. Influenza Virus–Specific Human Antibody Repertoire Studies

    Article • The Journal of Immunology, January 2019, The American Association of Immunologists

    Dr James E Crowe

  39. Regulating patterns of binding by changes in the heavy/light chain interface of HIV antibodies

    Article • Molecular Systems Design & Engineering, January 2019, Royal Society of Chemistry

    Dr James E Crowe

  40. Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth

    Article • PLOS One, December 2018, PLOS

    Dr James E Crowe

  41. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine

    Article • Journal of Virology, December 2018, ASM Journals

    Dr James E Crowe

  42. Current Understanding of Humoral Immunity to Enterovirus D68

    Article • Journal of the Pediatric Infectious Diseases Society, December 2018, Oxford University Press (OUP)

    Dr James E Crowe

  43. Human Monoclonal Antibodies That Neutralize Pandemic GII.4 Noroviruses

    Article • Gastroenterology, December 2018, Elsevier

    Dr James E Crowe

  44. Human mAbs to Staphylococcus aureus IsdA Provide Protection Through Both Heme-Blocking and Fc-Mediated Mechanisms

    Article • The Journal of Infectious Diseases, November 2018, Oxford University Press (OUP)

    Dr James E Crowe

  45. Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein

    Article • Nature Microbiology, November 2018, Springer Science + Business Media

    Dr James E Crowe

  46. A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions

    Article • Nature Microbiology, November 2018, Springer Science + Business Media

    Dr James E Crowe

  47. Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection

    Article • Cell Host & Microbe, November 2018, Elsevier

    Dr Stuart C. Ray, Dr James E Crowe

  48. HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design

    Article • Cell Host & Microbe, November 2018, Elsevier

    Dr James E Crowe

  49. In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model

    Article • Cell Reports, November 2018, Elsevier

    Dr James E Crowe

  50. Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine

    Article • Journal of Virology, September 2018, ASM Journals

    Dr James E Crowe

  51. Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap

    Article • PLoS Pathogens, August 2018, PLOS

    Dr James E Crowe

  52. Pan-Filovirus Serum Neutralizing Antibodies in a Subset of Congolese Ebolavirus Infection Survivors

    Article • The Journal of Infectious Diseases, August 2018, Oxford University Press (OUP)

    Dr James E Crowe

  53. Antibody Repertoires to the Same Ebola Vaccine Antigen Are Differentially Affected by Vaccine Vectors

    Article • Cell Reports, August 2018, Elsevier

    Palaniappan Ramanathan, Dr James E Crowe

  54. Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors

    Article • Cell Reports, August 2018, Elsevier

    Palaniappan Ramanathan, Dr James E Crowe

  55. A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus

    Article • Cell Host & Microbe, August 2018, Elsevier

    Dr James E Crowe

  56. Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection

    Article • Cell, August 2018, Elsevier

    Dr James E Crowe

  57. A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA

    Article • Nature Communications, July 2018, Springer Science + Business Media

    Dr James E Crowe

  58. Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates

    Article • The Journal of Infectious Diseases, July 2018, Oxford University Press (OUP)

    Dr James E Crowe

  59. Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein

    Article • Immunity, July 2018, Elsevier

    Dr Robert H Carnahan, Dr James E Crowe

  60. Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection

    Article • Cell Host & Microbe, June 2018, Elsevier

    Dr James E Crowe

  61. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2–MPER region

    Article • Nature Microbiology, May 2018, Springer Science + Business Media

    Palaniappan Ramanathan, Dr James E Crowe

  62. Mxra8 is a receptor for multiple arthritogenic alphaviruses

    Article • Nature, May 2018, Springer Science + Business Media

    Dr James E Crowe

  63. Mouse and Human Monoclonal Antibodies Protect against Infection by Multiple Genotypes of Japanese Encephalitis Virus

    Article • mBio, February 2018, ASM Journals

    Dr James E Crowe

  64. Human antibody recognition of antigenic site IV on Pneumovirus fusion proteins

    Article • PLoS Pathogens, February 2018, PLOS

    Dr James E Crowe

  65. Integrating linear optimization with structural modeling to increase HIV neutralization breadth

    Article • PLoS Computational Biology, February 2018, PLOS

    Dr James E Crowe

  66. OUP accepted manuscript

    Article • The Journal of Infectious Diseases, January 2018, Oxford University Press (OUP)

    Dr James E Crowe

  67. The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding

    Article • Cell Host & Microbe, January 2018, Elsevier

    Dr James E Crowe

  68. Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms

    Article • Proceedings of the National Academy of Sciences, December 2017, Proceedings of the National Academy of Sciences

    Dr James E Crowe, Dr Stuart C. Ray

  69. Role of Non-local Interactions between CDR Loops in Binding Affinity of MR78 Antibody to Marburg Virus Glycoprotein

    Article • Structure, December 2017, Elsevier

    Dr James E Crowe

  70. Structure–function characterization of three human antibodies targeting the vaccinia virus adhesion molecule D8

    Article • Journal of Biological Chemistry, November 2017, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr James E Crowe

  71. Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans

    Article • Journal of Virology, October 2017, ASM Journals

    Dr James E Crowe

  72. Epitope and Paratope Mapping Reveals Temperature-Dependent Alterations in the Dengue-Antibody Interface

    Article • Structure, September 2017, Elsevier

    Dr James E Crowe

  73. Immune correlates of protection for dengue: State of the art and research agenda

    Article • Vaccine, August 2017, Elsevier

    Dr James E Crowe

  74. Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design

    Article • Cell Host & Microbe, August 2017, Elsevier

    Dr James E Crowe

  75. Is It Possible to Develop a “Universal” Influenza Virus Vaccine?

    Article • Cold Spring Harbor Perspectives in Biology, June 2017, Cold Spring Harbor Laboratory Press

    Dr James E Crowe

  76. Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques

    Article • PLoS Neglected Tropical Diseases, June 2017, PLOS

    Dr James E Crowe

  77. Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance

    Article • JCI Insight, May 2017, American Society for Clinical Investigation

    Dr Stuart C. Ray, Dr James E Crowe

  78. Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody

    Article • Science Translational Medicine, April 2017, American Association for the Advancement of Science

    Dr James E Crowe

  79. Treating Flu with Skin of Frog

    Article • Immunity, April 2017, Elsevier

    Dr James E Crowe

  80. A human antibody against Zika virus crosslinks the E protein to prevent infection

    Article • Nature Communications, March 2017, Nature

    Dr James E Crowe

  81. Monoclonal Antibodies Against the Staphylococcus aureus Bicomponent Leukotoxin AB Isolated Following Invasive Human Infection Reveal Diverse Binding and Modes of Action

    Article • The Journal of Infectious Diseases, February 2017, Oxford University Press (OUP)

    Isaac Thomsen, Dr James E Crowe

  82. Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis

    Article • Science Translational Medicine, February 2017, American Association for the Advancement of Science

    Dr James E Crowe

  83. A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein

    Article • Nature Microbiology, January 2017, Nature

    Dr James E Crowe

  84. Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus

    Article • Nature Microbiology, January 2017, Nature

    Dr James E Crowe

  85. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination

    Article • Journal of Virology, December 2016, ASM Journals

    Dr James E Crowe

  86. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice

    Article • Nature, November 2016, Nature

    Dr James E Crowe

  87. Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein

    Article • Proceedings of the National Academy of Sciences, October 2016, Proceedings of the National Academy of Sciences

    Dr James E Crowe

  88. Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections

    Article • Cell, October 2016, Elsevier

    Dr James E Crowe

  89. Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody

    Article • Proceedings of the National Academy of Sciences, September 2016, Proceedings of the National Academy of Sciences

    Dr James E Crowe

  90. A “Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses

    Article • Science, September 2016, American Association for the Advancement of Science

    Dr James E Crowe

  91. Teaching a Clone to Walk, One Step at a Time

    Article • Cell, September 2016, Elsevier

    Dr James E Crowe

  92. Phenome-Wide Association Study to Explore Relationships between Immune System Related Genetic Loci and Complex Traits and Diseases

    Article • PLOS One, August 2016, PLOS

    Dr James E Crowe

  93. Structures of Ebola virus GP and sGP in complex with therapeutic antibodies

    Article • Nature Microbiology, August 2016, Springer Science + Business Media

    Dr James E Crowe

  94. Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence

    Article • Cell Reports, August 2016, Elsevier

    Dr James E Crowe

  95. Human Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein

    Article • PLOS One, July 2016, PLOS

    Dr James E Crowe

  96. Determinants of VH1-46 Cross-Reactivity to Pemphigus Vulgaris Autoantigen Desmoglein 3 and Rotavirus Antigen VP6

    Article • The Journal of Immunology, July 2016, The American Association of Immunologists

    Dr James E Crowe

  97. Recognition of influenza H3N2 variant virus by human neutralizing antibodies

    Article • JCI Insight, July 2016, American Society for Clinical Investigation

    Dr James E Crowe

  98. Frequent Use of the IgA Isotype in Human B Cells Encoding Potent Norovirus-Specific Monoclonal Antibodies That Block HBGA Binding

    Article • PLoS Pathogens, June 2016, PLOS

    Dr James E Crowe

  99. Characterization of dengue virus 2 growth in megakaryocyte–erythrocyte progenitor cells

    Article • Virology, June 2016, Elsevier

    Dr James E Crowe

  100. Deep sequencing and human antibody repertoire analysis

    Article • Current Opinion in Immunology, June 2016, Elsevier

    Dr James E Crowe

  101. A Chimeric Pneumovirus Fusion Protein Carrying Neutralizing Epitopes of Both MPV and RSV

    Article • PLOS One, May 2016, PLOS

    Dr James E Crowe

  102. Engineering Recombinant Reoviruses To Display gp41 Membrane-Proximal External-Region Epitopes from HIV-1

    Article • mSphere, May 2016, ASM Journals

    Terence Dermody, Dr James E Crowe

  103. Improving Loop Modeling of the Antibody Complementarity-Determining Region 3 Using Knowledge-Based Restraints

    Article • PLOS One, May 2016, PLOS

    Dr James E Crowe

  104. Long antibody HCDR3s from HIV-naïve donors presented on a PG9 neutralizing antibody background mediate HIV neutralization

    Article • Proceedings of the National Academy of Sciences, April 2016, Proceedings of the National Academy of Sciences

    Dr James E Crowe

  105. Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1

    Article • Journal of Virology, March 2016, ASM Journals

    Dr James E Crowe

  106. H7N9 influenza virus neutralizing antibodies that possess few somatic mutations

    Article • Journal of Clinical Investigation, March 2016, American Society for Clinical Investigation

    Dr James E Crowe, Dr Randy A Albrecht

  107. Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies

    Article • mBio, February 2016, ASM Journals

    Dr James E Crowe

  108. Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations

    Article • Molecular Immunology, February 2016, Elsevier

    Dr James E Crowe

  109. Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates

    Article • Vaccine, February 2016, Elsevier

    Dr James E Crowe

  110. Chimeric Filoviruses for Identification and Characterization of Monoclonal Antibodies

    Article • Journal of Virology, January 2016, ASM Journals

    Dr James E Crowe

  111. Early Th1 immunity promotes immune tolerance and may impair graft-versus-leukemia effect after allogeneic hematopoietic cell transplantation

    Article • Haematologica, January 2016, Ferrata Storti Foundation (Haematologica)

    Dr James E Crowe

  112. Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection

    Article • Cell, January 2016, Elsevier

    Dr James E Crowe

  113. Development of Human Monoclonal Antibodies Against Respiratory Syncytial Virus Using a High Efficiency Human Hybridoma Technique

    Article • January 2016, Springer Science + Business Media

    Dr James E Crowe

  114. Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress

    Article • Cell, November 2015, Elsevier

    Dr James E Crowe

  115. Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site

    Article • Journal of Virology, October 2015, ASM Journals

    Dr James E Crowe

  116. Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity

    Article • Proceedings of the National Academy of Sciences, October 2015, Proceedings of the National Academy of Sciences

    Dr James E Crowe

  117. A New Quaternary Structure Epitope on Dengue Virus Serotype 2 Is the Target of Durable Type-Specific Neutralizing Antibodies

    Article • mBio, October 2015, ASM Journals

    Dr James E Crowe

  118. Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus

    Article • Cell Host & Microbe, September 2015, Elsevier

    Dr James E Crowe

  119. Deciphering the human immunome

    Article • Expert Review of Vaccines, August 2015, Informa Healthcare

    Dr James E Crowe

  120. Source and Purity of Dengue-Viral Preparations Impact Requirement for Enhancing Antibody to Induce Elevated IL-1β Secretion: A Primary Human Monocyte Model

    Article • PLOS One, August 2015, PLOS

    Dr James E Crowe

  121. Association of VH4-59 Antibody Variable Gene Usage with Recognition of an Immunodominant Epitope on the HIV-1 Gag Protein

    Article • PLOS One, July 2015, PLOS

    Dr James E Crowe

  122. Vaccine-elicited antibody that neutralizes H5N1 influenza and variants binds the receptor site and polymorphic sites

    Article • Proceedings of the National Academy of Sciences, July 2015, Proceedings of the National Academy of Sciences

    Dr James E Crowe

  123. Design of Protein Multi-specificity Using an Independent Sequence Search Reduces the Barrier to Low Energy Sequences

    Article • PLoS Computational Biology, July 2015, PLOS

    Dr James E Crowe

  124. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers

    Article • Science, July 2015, American Association for the Advancement of Science

    Dr James E Crowe

  125. Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus

    Article • Cell Host & Microbe, July 2015, Elsevier

    Dr James E Crowe

  126. Spleen Tyrosine Kinase (Syk) Mediates IL-1β Induction by Primary Human Monocytes during Antibody-enhanced Dengue Virus Infection

    Article • Journal of Biological Chemistry, June 2015, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr James E Crowe

  127. Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth

    Article • Journal of Clinical Investigation, May 2015, American Society for Clinical Investigation

    Dr James E Crowe, Dr Jean-Philippe Julien

  128. Retraction for Messer et al., Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity

    Article • Proceedings of the National Academy of Sciences, May 2015, Proceedings of the National Academy of Sciences

    Dr James E Crowe

  129. Challenges and Opportunities in Developing Respiratory Syncytial Virus Therapeutics

    Article • The Journal of Infectious Diseases, February 2015, Oxford University Press (OUP)

    Dr James E Crowe

  130. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins

    Article • Nature Communications, February 2015, Springer Science + Business Media

    Dr James E Crowe

  131. Mechanism of Human Antibody-Mediated Neutralization of Marburg Virus

    Article • Cell, February 2015, Elsevier

    Dr James E Crowe

  132. Structural Basis for Marburg Virus Neutralization by a Cross-Reactive Human Antibody

    Article • Cell, February 2015, Elsevier

    Dr James E Crowe

  133. Influenza Viruses with Receptor-Binding N1 Neuraminidases Occur Sporadically in Several Lineages and Show No Attenuation in Cell Culture or Mice

    Article • Journal of Virology, January 2015, ASM Journals

    Dr James E Crowe

  134. Antibodies for Infectious Diseases

    Article • January 2015, ASM Journals

    Dr James E Crowe

  135. Use of Human Hybridoma Technology To Isolate Human Monoclonal Antibodies

    Article • January 2015, ASM Journals

    Dr James E Crowe

  136. Committing the Oldest Sins in the Newest Kind of Ways—Antibodies Targeting the Influenza Virus Type A Hemagglutinin Globular Head

    Article • January 2015, ASM Journals

    Dr James E Crowe

  137. Identification of Residues in the Human Respiratory Syncytial Virus Fusion Protein That Modulate Fusion Activity and Pathogenesis

    Article • Journal of Virology, October 2014, ASM Journals

    Dr James E Crowe

  138. Dengue Viruses Are Enhanced by Distinct Populations of Serotype Cross-Reactive Antibodies in Human Immune Sera

    Article • PLoS Pathogens, October 2014, PLOS

    Dr James E Crowe

  139. Isolation of Dengue Virus-Specific Memory B Cells with Live Virus Antigen from Human Subjects following Natural Infection Reveals the Presence of Diverse Novel Functional Groups of Antibody Clones

    Article • Journal of Virology, August 2014, ASM Journals

    Dr James E Crowe

  140. Intracellular neutralization of a virus using a cell-penetrating molecular transporter

    Article • Nanomedicine, August 2014, Future Medicine

    Dr James E Crowe

  141. Tissue-Specific Expressed Antibody Variable Gene Repertoires

    Article • PLOS One, June 2014, PLOS

    Dr James E Crowe

  142. STAT4 Deficiency Fails To Induce Lung Th2 or Th17 Immunity following Primary or Secondary Respiratory Syncytial Virus (RSV) Challenge but Enhances the Lung RSV-Specific CD8+ T Cell Immune Response to Secondary Challenge

    Article • Journal of Virology, June 2014, ASM Journals

    Dr James E Crowe

  143. Correction for Messer et al., Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity

    Article • Proceedings of the National Academy of Sciences, April 2014, Proceedings of the National Academy of Sciences

    Dr James E Crowe

  144. Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein

    Article • Virology, April 2014, Elsevier

    Dr James E Crowe

  145. Antibody Engineering and Therapeutics

    Article • mAbs, March 2014, Taylor & Francis

    Dr James E Crowe

  146. Proof of principle for epitope-focused vaccine design

    Article • Nature, February 2014, Nature

    Dr James E Crowe

  147. Combining Single RNA Sensitive Probes with Subdiffraction-Limited and Live-Cell Imaging Enables the Characterization of Virus Dynamics in Cells

    Article • ACS Nano, January 2014, American Chemical Society (ACS)

    Dr James E Crowe

  148. Diagnostic errors in interpretation of pediatric musculoskeletal radiographs at common injury sites

    Article • Pediatric Radiology, January 2014, Springer Science + Business Media

    Dr James E Crowe

  149. Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity

    Article • Proceedings of the National Academy of Sciences, January 2014, Proceedings of the National Academy of Sciences

    Dr James E Crowe

  150. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface

    Article • EMBO Molecular Medicine, January 2014, EMBO

    Dr James E Crowe

  151. Paramyxoviruses: Respiratory Syncytial Virus and Human Metapneumovirus

    Article • January 2014, Springer Science + Business Media

    Dr James E Crowe

  152. The Potent and Broadly Neutralizing Human Dengue Virus-Specific Monoclonal Antibody 1C19 Reveals a Unique Cross-Reactive Epitope on the bc Loop of Domain II of the Envelope Protein

    Article • mBio, November 2013, ASM Journals

    Dr James E Crowe

  153. Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses

    Article • Journal of Clinical Investigation, November 2013, American Society for Clinical Investigation

    Dr James E Crowe

  154. Differential Accessibility of a Rotavirus VP6 Epitope in Trimers Comprising Type I, II, or III Channels as Revealed by Binding of a Human Rotavirus VP6-Specific Antibody

    Article • Journal of Virology, October 2013, ASM Journals

    Dr James E Crowe

  155. Impact of new sequencing technologies on studies of the human B cell repertoire

    Article • Current Opinion in Immunology, October 2013, Elsevier

    Dr James E Crowe

  156. Intermittent Testicular Torsion in the Pediatric Patient: Sonographic Indicators of a Difficult Diagnosis

    Article • American Journal of Roentgenology, October 2013, American Roentgen Ray Society

    Dr James E Crowe

  157. Antibody Recognition of the Pandemic H1N1 Influenza Virus Hemagglutinin Receptor Binding Site

    Article • Journal of Virology, September 2013, ASM Journals

    Dr James E Crowe

  158. Exposure to Family Members: Infections and Recent Live Vaccinations

    Article • September 2013, Wiley

    Dr James E Crowe

  159. Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses

    Article • Journal of Clinical Investigation, September 2013, American Society for Clinical Investigation

    Dr James E Crowe

  160. Universal Flu Vaccines: Primum non nocere

    Article • Science Translational Medicine, August 2013, American Association for the Advancement of Science

    Dr James E Crowe

  161. Gold nanorod vaccine for respiratory syncytial virus

    Article • Nanotechnology, June 2013, Institute of Physics Publishing

    Dr James E Crowe

  162. Anti Rotavirus Antibody

    Article • May 2013, Protein Data Bank, Rutgers University

    Dr James E Crowe

  163. Human Rotavirus VP6-Specific Antibodies Mediate Intracellular Neutralization by Binding to a Quaternary Structure in the Transcriptional Pore

    Article • PLOS One, May 2013, PLOS

    Dr James E Crowe

  164. Crowdsourcing Immunity

    Article • Science, May 2013, American Association for the Advancement of Science

    Dr James E Crowe

  165. Human Germline Antibody Gene Segments Encode Polyspecific Antibodies

    Article • PLoS Computational Biology, April 2013, PLOS

    Dr James E Crowe

  166. E107 Complexity of human naïve B cell repertoires

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, April 2013, Wolters Kluwer Health

    Dr James E Crowe

  167. Discovering naturally processed antigenic determinants that confer protective T cell immunity

    Article • Journal of Clinical Investigation, April 2013, American Society for Clinical Investigation

    Dr James E Crowe

  168. Human Monoclonal Antibodies Derived From Memory B Cells Following Live Attenuated Dengue Virus Vaccination or Natural Infection Exhibit Similar Characteristics

    Article • The Journal of Infectious Diseases, March 2013, Oxford University Press (OUP)

    Dr James E Crowe

  169. Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model

    Article • mAbs, March 2013, Taylor & Francis

    Dr James E Crowe

  170. Reversion of Somatic Mutations of the Respiratory Syncytial Virus-Specific Human Monoclonal Antibody Fab19 Reveal a Direct Relationship between Association Rate and Neutralizing Potency

    Article • The Journal of Immunology, March 2013, The American Association of Immunologists

    Dr James E Crowe

  171. A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin

    Article • Nature Structural & Molecular Biology, February 2013, Springer Science + Business Media

    Dr James E Crowe

  172. Secondary mechanisms of diversification in the human antibody repertoire

    Article • Frontiers in Immunology, January 2013, Frontiers

    Dr James E Crowe

  173. Molecular mechanisms driving respiratory syncytial virus assembly

    Article • Future Microbiology, January 2013, Future Medicine

    Dr James E Crowe

  174. Respiratory Syncytial Virus Regulates Human MicroRNAs by Using Mechanisms Involving Beta Interferon and NF-κB

    Article • mBio, December 2012, ASM Journals

    Dr James E Crowe

  175. Influenza Human Monoclonal Antibody 1F1 Interacts with Three Major Antigenic Sites and Residues Mediating Human Receptor Specificity in H1N1 Viruses

    Article • PLoS Pathogens, December 2012, PLOS

    Dr James E Crowe

  176. A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis

    Article • Virology, December 2012, Elsevier

    Dr James E Crowe

  177. Tissue-specific regulatory T cells: biomarker for acute graft-vs-host disease and survival

    Article • Experimental Hematology, December 2012, Elsevier

    Dr James E Crowe

  178. Unusual Features of Vaccinia Virus Extracellular Virion Form Neutralization Resistance Revealed in Human Antibody Responses to the Smallpox Vaccine

    Article • Journal of Virology, November 2012, ASM Journals

    Dr James E Crowe

  179. Erratum: Corrigendum: Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors

    Article • Nature, September 2012, Springer Science + Business Media

    Dr James E Crowe

  180. A Chemically Programmed Antibody Is a Long-Lasting and Potent Inhibitor of Influenza Neuraminidase

    Article • ChemBioChem, September 2012, Wiley

    Dr James E Crowe

  181. Frequency and genetic characterization of V(DD)J recombinants in the human peripheral blood antibody repertoire

    Article • Immunology, August 2012, Wiley

    Dr James E Crowe

  182. Influenza Virus Resistance to Human Neutralizing Antibodies

    Article • mBio, July 2012, ASM Journals

    Dr James E Crowe

  183. Respiratory Syncytial Virus Assembles into Structured Filamentous Virion Particles Independently of Host Cytoskeleton and Related Proteins

    Article • PLOS One, July 2012, PLOS

    Dr James E Crowe

  184. Location and length distribution of somatic hypermutation-associated DNA insertions and deletions reveals regions of antibody structural plasticity

    Article • Genes & Immunity, June 2012, Nature

    Dr James E Crowe

  185. High-throughput antibody sequencing reveals genetic evidence of global regulation of the naïve and memory repertoires that extends across individuals

    Article • Genes & Immunity, May 2012, Nature

    Dr James E Crowe

  186. Human Respiratory Syncytial Virus Nucleoprotein and Inclusion Bodies Antagonize the Innate Immune Response Mediated by MDA5 and MAVS

    Article • Journal of Virology, May 2012, ASM Journals

    Dr James E Crowe

  187. Human Peripheral Blood Antibodies with Long HCDR3s Are Established Primarily at Original Recombination Using a Limited Subset of Germline Genes

    Article • PLOS One, May 2012, PLOS

    Dr James E Crowe

  188. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions

    Article • Proceedings of the National Academy of Sciences, April 2012, Proceedings of the National Academy of Sciences

    Dr James E Crowe

  189. Human Monoclonal Antibodies to Pandemic 1957 H2N2 and Pandemic 1968 H3N2 Influenza Viruses

    Article • Journal of Virology, March 2012, ASM Journals

    Dr James E Crowe, Dr Randy A Albrecht

  190. Structure of the human metapneumovirus fusion protein with neutralizing antibody identifies a pneumovirus antigenic site

    Article • Nature Structural & Molecular Biology, March 2012, Springer Science + Business Media

    John Williams, Dr James E Crowe

  191. A Critical Phenylalanine Residue in the Respiratory Syncytial Virus Fusion Protein Cytoplasmic Tail Mediates Assembly of Internal Viral Proteins into Viral Filaments and Particles

    Article • mBio, February 2012, ASM Journals

    Dr James E Crowe

  192. Predicting posttransplantation diabetes mellitus by regulatory T-cell phenotype: implications for metabolic intervention to modulate alloreactivity

    Article • Blood, January 2012, American Society of Hematology

    Dr James E Crowe, Daniel Moore

  193. Independent Structural Domains in Paramyxovirus Polymerase Protein

    Article • Journal of Biological Chemistry, January 2012, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr James E Crowe

  194. Viral Pneumonia

    Article • January 2012, Elsevier

    Dr James E Crowe

  195. Persistence of Circulating Memory B Cell Clones with Potential for Dengue Virus Disease Enhancement for Decades following Infection

    Article • Journal of Virology, December 2011, ASM Journals

    Dr James E Crowe

  196. Identification of potential human respiratory syncytial virus and metapneumovirus T cell epitopes using computational prediction and MHC binding assays

    Article • Journal of Immunological Methods, November 2011, Elsevier

    Dr James E Crowe

  197. Machine learning competition in immunology – Prediction of HLA class I binding peptides

    Article • Journal of Immunological Methods, November 2011, Elsevier

    Dr James E Crowe, Prof Gajendra PS Raghava

  198. Maturation-Induced Cloaking of Neutralization Epitopes on HIV-1 Particles

    Article • PLoS Pathogens, September 2011, PLOS

    Dr James E Crowe

  199. Epitope-Specific Human Influenza Antibody Repertoires Diversify by B Cell Intraclonal Sequence Divergence and Interclonal Convergence

    Article • The Journal of Immunology, August 2011, The American Association of Immunologists

    Dr James E Crowe

  200. A Broadly Neutralizing Human Monoclonal Antibody That Recognizes a Conserved, Novel Epitope on the Globular Head of the Influenza H1N1 Virus Hemagglutinin

    Article • Journal of Virology, August 2011, ASM Journals

    Dr James E Crowe

  201. Tribute to David T. Karzon, MD and Robert M. Chanock, MD

    Article • Vaccine, May 2011, Elsevier

    Dr James E Crowe

  202. Activation of protein kinase R is required for induction of stress granules by respiratory syncytial virus but dispensable for viral replication

    Article • Virology, April 2011, Elsevier

    Dr James E Crowe

  203. An Insertion Mutation That Distorts Antibody Binding Site Architecture Enhances Function of a Human Antibody

    Article • mBio, February 2011, ASM Journals

    Dr James E Crowe

  204. Research Highlights

    Article • Nanomedicine, January 2011, Future Medicine

    Dr James E Crowe

  205. Human Metapneumovirus

    Article • January 2011, Elsevier

    Dr James E Crowe

  206. Respiratory Syncytial Virus

    Article • January 2011, Elsevier

    Dr James E Crowe

  207. Prevention of Fetal and Early Life Infections Through Maternal–Neonatal Immunization

    Article • January 2011, Elsevier

    Dr James E Crowe

  208. Respiratory Syncytial Virus and Human Metapneumovirus

    Article • January 2011, ASM Journals

    Dr James E Crowe

  209. Reply to Schlapbach et al

    Article • The Journal of Infectious Diseases, December 2010, Oxford University Press (OUP)

    Dr James E Crowe

  210. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes

    Article • Nature Medicine, December 2010, Nature

    Dr James E Crowe

  211. Specificity for Human Hemoglobin Enhances Staphylococcus aureus Infection

    Article • Cell Host & Microbe, December 2010, Elsevier

    Dr Eric P Skaar, Dr James E Crowe

  212. Faculty of 1000 evaluation for A size threshold limits prion transmission and establishes phenotypic diversity.

    Article • October 2010, Faculty of 1000, Ltd.

    Dr James E Crowe

  213. Transforming Growth Factor Beta Is a Major Regulator of Human Neonatal Immune Responses following Respiratory Syncytial Virus Infection

    Article • Journal of Virology, October 2010, ASM Journals

    Dr James E Crowe

  214. Respiratory Syncytial Virus Induces Host RNA Stress Granules To Facilitate Viral Replication

    Article • Journal of Virology, September 2010, ASM Journals

    Dr James E Crowe

  215. Surfing a genetic association interaction network to identify modulators of antibody response to smallpox vaccine

    Article • Genes & Immunity, July 2010, Nature

    Dr James E Crowe

  216. Pseudovirion Particles Bearing Native HIV Envelope Trimers Facilitate a Novel Method for Generating Human Neutralizing Monoclonal Antibodies Against HIV

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, July 2010, Wolters Kluwer Health

    Dr James E Crowe

  217. Population‐Based Incidence of Human Metapneumovirus Infection among Hospitalized Children

    Article • The Journal of Infectious Diseases, June 2010, Oxford University Press (OUP)

    John Williams, Dr James E Crowe

  218. Regulatory T cell expression of CLA or α4β7 and skin or gut acute GVHD outcomes

    Article • British Journal of Pharmacology, May 2010, Nature

    Dr James E Crowe

  219. Emerging studies of human HIV-specific antibody repertoires

    Article • Vaccine, May 2010, Elsevier

    Dr James E Crowe

  220. Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza Virus

    Article • Science, March 2010, American Association for the Advancement of Science

    Dr James E Crowe

  221. Naturally Occurring Human Monoclonal Antibodies Neutralize both 1918 and 2009 Pandemic Influenza A (H1N1) Viruses

    Article • Journal of Virology, December 2009, ASM Journals

    Dr James E Crowe

  222. Faculty of 1000 evaluation for Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial.

    Article • December 2009, Faculty of 1000, Ltd.

    Dr James E Crowe

  223. Faculty of 1000 evaluation for Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus.

    Article • December 2009, Faculty of 1000, Ltd.

    Dr James E Crowe

  224. Recent advances in the study of human antibody responses to influenza virus using optimized human hybridoma approaches

    Article • Vaccine, December 2009, Elsevier

    Dr James E Crowe

  225. The human neonatal B cell response to respiratory syncytial virus uses a biased antibody variable gene repertoire that lacks somatic mutations

    Article • Molecular Immunology, December 2009, Elsevier

    Dr James E Crowe

  226. Genetic diversity and evolution of human metapneumovirus fusion protein over twenty years

    Article • Virology Journal, September 2009, Springer Science + Business Media

    John Williams, Dr James E Crowe

  227. Faculty of 1000 evaluation for Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

    Article • September 2009, Faculty of 1000, Ltd.

    Dr James E Crowe

  228. The Pediatric Burden of Human Coronaviruses Evaluated for Twenty Years

    Article • The Pediatric Infectious Disease Journal, August 2009, Wolters Kluwer Health

    Dr James E Crowe

  229. Coronavirus infection and hospitalizations for acute respiratory illness in young children

    Article • Journal of Medical Virology, May 2009, Wiley

    Dr James E Crowe

  230. Single molecule–sensitive probes for imaging RNA in live cells

    Article • Nature Chemical Biology, April 2009, Springer Science + Business Media

    Dr James E Crowe

  231. Amphiregulin-Deficient Mice Develop Spasmolytic Polypeptide Expressing Metaplasia and Intestinal Metaplasia

    Article • Gastroenterology, April 2009, Elsevier

    Dr James E Crowe

  232. Capturing the Spectrum of Interaction Effects in Genetic Association Studies by Simulated Evaporative Cooling Network Analysis

    Article • PLoS Genetics, March 2009, PLOS

    Dr James E Crowe

  233. Faculty of 1000 evaluation for Antibody recognition of a highly conserved influenza virus epitope.

    Article • March 2009, Faculty of 1000, Ltd.

    Dr James E Crowe

  234. Faculty of 1000 evaluation for Antigen-specific human polyclonal antibodies from hyperimmunized cattle.

    Article • February 2009, Faculty of 1000, Ltd.

    Dr James E Crowe

  235. Faculty of 1000 evaluation for Estrogen directly activates AID transcription and function.

    Article • February 2009, Faculty of 1000, Ltd.

    Dr James E Crowe

  236. A Chimeric A2 Strain of Respiratory Syncytial Virus (RSV) with the Fusion Protein of RSV Strain Line 19 Exhibits Enhanced Viral Load, Mucus, and Airway Dysfunction

    Article • Journal of Virology, February 2009, ASM Journals

    Dr James E Crowe

  237. Faculty of 1000 evaluation for Engineering microRNA responsiveness to decrease virus pathogenicity.

    Article • November 2008, Faculty of 1000, Ltd.

    Dr James E Crowe

  238. Human metapneumovirus nucleoprotein and phosphoprotein interact and provide the minimal requirements for inclusion body formation

    Article • Journal of General Virology, October 2008, Society for General Microbiology

    Dr James E Crowe

  239. Integrated analysis of genetic and proteomic data identifies biomarkers associated with adverse events following smallpox vaccination

    Article • Genes & Immunity, October 2008, Nature

    Dr James E Crowe

  240. An Alphavirus Replicon-Based Human Metapneumovirus Vaccine Is Immunogenic and Protective in Mice and Cotton Rats

    Article • Journal of Virology, September 2008, ASM Journals

    Dr James E Crowe

  241. Enhancement of the CD8+ T cell response to a subdominant epitope of respiratory syncytial virus by deletion of an immunodominant epitope

    Article • Vaccine, September 2008, Elsevier

    Dr James E Crowe

  242. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors

    Article • Nature, August 2008, Springer Science + Business Media

    Dr James E Crowe

  243. Respiratory syncytial virus uses a Vps4-independent budding mechanism controlled by Rab11-FIP2

    Article • Proceedings of the National Academy of Sciences, July 2008, Proceedings of the National Academy of Sciences

    Dr James E Crowe

  244. Genetic Basis for Adverse Events after Smallpox Vaccination

    Article • The Journal of Infectious Diseases, July 2008, Oxford University Press (OUP)

    Dr James E Crowe

  245. An optimized electrofusion-based protocol for generating virus-specific human monoclonal antibodies

    Article • Journal of Immunological Methods, July 2008, Elsevier

    Dr James E Crowe

  246. Functional Maturation of the Human Antibody Response to Rotavirus

    Article • The Journal of Immunology, March 2008, The American Association of Immunologists

    Dr Bidadi V Prasad, Dr James E Crowe

  247. Immunodominance of the VH1-46 Antibody Gene Segment in the Primary Repertoire of Human Rotavirus-Specific B Cells Is Reduced in the Memory Compartment through Somatic Mutation of Nondominant Clones

    Article • The Journal of Immunology, February 2008, The American Association of Immunologists

    Dr James E Crowe

  248. A Clinical Isolate Strain of Respiratory Syncytial Virus (RSV) Causes Airway Obstruction and Histopathology in Mice Similar to Severe RSV Disease in Infants

    Article • Journal of Allergy and Clinical Immunology, February 2008, Elsevier

    Dr James E Crowe

  249. Human Metapneumovirus

    Article • January 2008, Elsevier

    John Williams, Dr James E Crowe

  250. Respiratory Syncytial Virus

    Article • January 2008, Elsevier

    Dr James E Crowe

  251. Faculty of 1000 evaluation for Duration of humoral immunity to common viral and vaccine antigens.

    Article • November 2007, Faculty of 1000, Ltd.

    Dr James E Crowe

  252. Faculty of 1000 evaluation for Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.

    Article • October 2007, Faculty of 1000, Ltd.

    Dr James E Crowe

  253. Faculty of 1000 evaluation for A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis.

    Article • October 2007, Faculty of 1000, Ltd.

    Dr James E Crowe

  254. Venezuelan Equine Encephalitis Virus Replicon Particles Encoding Respiratory Syncytial Virus Surface Glycoproteins Induce Protective Mucosal Responses in Mice and Cotton Rats

    Article • Journal of Virology, October 2007, ASM Journals

    Dr James E Crowe

  255. Genetic Predisposition for Adverse Events after Vaccination

    Article • The Journal of Infectious Diseases, July 2007, Oxford University Press (OUP)

    Dr James E Crowe

  256. Evaporative cooling feature selection for genotypic data involving interactions

    Article • Bioinformatics, June 2007, Oxford University Press (OUP)

    Dr James E Crowe

  257. A Recombinant Human Monoclonal Antibody to Human Metapneumovirus Fusion Protein That Neutralizes Virus In Vitro and Is Effective Therapeutically In Vivo

    Article • Journal of Virology, May 2007, ASM Journals

    Dr James E Crowe

  258. Evidence for preferential Ig gene usage and differential TdT and exonuclease activities in human naïve and memory B cells

    Article • Molecular Immunology, March 2007, Elsevier

    Dr James E Crowe

  259. Faculty of 1000 evaluation for Ab and T cell epitopes of influenza A virus, knowledge and opportunities.

    Article • February 2007, Faculty of 1000, Ltd.

    Dr James E Crowe

  260. Using the natural evolution of a rotavirus-specific human monoclonal antibody to predict the complex topography of a viral antigenic site

    Article • Immunome Research, January 2007, Springer Science + Business Media

    Dr James E Crowe

  261. Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools

    Article • Journal of Molecular Recognition, January 2007, Wiley

    Dr James E Crowe, Prof Gajendra PS Raghava, Dr. Erwin L J Roggen

  262. Tissue-Specific Regulation of CD8+ T-Lymphocyte Immunodominance in Respiratory Syncytial Virus Infection

    Article • Journal of Virology, December 2006, ASM Journals

    Dr James E Crowe

  263. Faculty of 1000 evaluation for The histopathology of fatal untreated human respiratory syncytial virus infection.

    Article • December 2006, Faculty of 1000, Ltd.

    Dr James E Crowe

  264. Faculty of 1000 evaluation for Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins.

    Article • December 2006, Faculty of 1000, Ltd.

    Dr James E Crowe

  265. Nanoscale tools for rapid and sensitive diagnosis of viruses

    Article • Future Virology, November 2006, Future Medicine

    Dr James E Crowe

  266. Faculty of 1000 evaluation for Low-coverage vaccination strategies for the conservation of endangered species.

    Article • October 2006, Faculty of 1000, Ltd.

    Dr James E Crowe

  267. Human Metapneumovirus Fusion Protein Vaccines That Are Immunogenic and Protective in Cotton Rats

    Article • Journal of Virology, October 2006, ASM Journals

    Dr James E Crowe

  268. Examination of a Fusogenic Hexameric Core from Human Metapneumovirus and Identification of a Potent Synthetic Peptide Inhibitor from the Heptad Repeat 1 Region

    Article • Journal of Virology, October 2006, ASM Journals

    Dr James E Crowe

  269. Introduction

    Article • Seminars in Pediatric Infectious Diseases, October 2006, Elsevier

    Dr James E Crowe

  270. Low expression of the interleukin (IL)-4 receptor alpha chain and reduced signalling via the IL-4 receptor complex in human neonatal B cells

    Article • Immunology, September 2006, Wiley

    Dr James E Crowe

  271. Feature Selection using a Random Forests Classifier for the Integrated Analysis of Multiple Data Types

    Article • September 2006, Institute of Electrical & Electronics Engineers (IEEE)

    Dr James E Crowe

  272. Cellular Immune Responses to Diluted and Undiluted Aventis Pasteur Smallpox Vaccine

    Article • The Journal of Infectious Diseases, August 2006, Oxford University Press (OUP)

    Dr James E Crowe, Dr Thomas R Talbot

  273. Cytokine Expression Patterns Associated with Systemic Adverse Events following Smallpox Immunization

    Article • The Journal of Infectious Diseases, August 2006, Oxford University Press (OUP)

    Dr James E Crowe

  274. Faculty of 1000 evaluation for A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines.

    Article • July 2006, Faculty of 1000, Ltd.

    Dr James E Crowe

  275. Faculty of 1000 evaluation for Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants.

    Article • July 2006, Faculty of 1000, Ltd.

    Dr James E Crowe

  276. :Vaccines: Frontiers in Design and Development

    Article • Clinical Infectious Diseases, July 2006, Oxford University Press (OUP)

    Dr James E Crowe

  277. Automated image analysis of atomic force microscopy images of rotavirus particles

    Article • Ultramicroscopy, June 2006, Elsevier

    Dr James E Crowe

  278. Hybrid grammar-based approach to nonlinear dynamical system identification from biological time series

    Article • Physical Review E, February 2006, American Physical Society (APS)

    Dr James E Crowe

  279. Detection of viral infections using colloidal quantum dots

    Article • February 2006, SPIE

    Dr James E Crowe

  280. The Role of Human Metapneumovirus in Upper Respiratory Tract Infections in Children: A 20‐Year Experience

    Article • The Journal of Infectious Diseases, February 2006, Oxford University Press (OUP)

    John Williams, Dr James E Crowe

  281. The Transmembrane Domain of the Respiratory Syncytial Virus F Protein Is an Orientation-Independent Apical Plasma Membrane Sorting Sequence

    Article • Journal of Virology, February 2006, ASM Journals

    Dr James E Crowe

  282. Viral Pneumonia

    Article • January 2006, Elsevier

    Dr James E Crowe

  283. Rotavirus-Specific CD5+ B Cells in Young Children Exhibit a Distinct Antibody Repertoire Compared with CD5− B Cells

    Article • Human Immunology, January 2006, Elsevier

    Dr James E Crowe

  284. Reply

    Article • Journal of Allergy and Clinical Immunology, January 2006, Elsevier

    Dr James E Crowe

  285. Transcriptional Control of Activation-Induced Cytidine Deaminase and Error-Prone DNA Polymerases Is Functionally Mature in the B Cells of Infants at Birth

    Article • Human Immunology, January 2006, Elsevier

    Dr James E Crowe

  286. Faculty of 1000 evaluation for Altered TCR signaling from geometrically repatterned immunological synapses.

    Article • November 2005, Faculty of 1000, Ltd.

    Dr James E Crowe

  287. Human Metapneumovirus Infection Plays an Etiologic Role in Acute Asthma Exacerbations Requiring Hospitalization in Adults

    Article • The Journal of Infectious Diseases, October 2005, Oxford University Press (OUP)

    John Williams, Dr James E Crowe

  288. The Transmembrane Domain of the Respiratory Syncytial Virus F Protein Is an Orientation-Independent Apical Plasma Membrane Sorting Sequence

    Article • Journal of Virology, October 2005, ASM Journals

    Dr James E Crowe

  289. Prospective Study of the Incidence, Clinical Features, and Outcome of Symptomatic Upper and Lower Respiratory Tract Infections by Respiratory Viruses in Adult Recipients of Hematopoietic Stem Cell Transplants for Hematologic Malignancies

    Article • Biology of Blood and Marrow Transplantation, October 2005, Elsevier

    Dr James E Crowe

  290. A Prospective Study Comparing Human Metapneumovirus with Other Respiratory Viruses in Adults with Hematologic Malignancies and Respiratory Tract Infections

    Article • The Journal of Infectious Diseases, September 2005, Oxford University Press (OUP)

    John Williams, Dr James E Crowe

  291. The Cotton Rat (Sigmodon hispidus) Is a Permissive Small Animal Model of Human Metapneumovirus Infection, Pathogenesis, and Protective Immunity

    Article • Journal of Virology, September 2005, ASM Journals

    Dr James E Crowe

  292. Identification of an H-2Db-restricted CD8+ cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virus

    Article • Virology, July 2005, Elsevier

    Dr James E Crowe

  293. Faculty of 1000 evaluation for Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

    Article • June 2005, Faculty of 1000, Ltd.

    Dr James E Crowe

  294. Human metapneumovirus infection in children hospitalized for wheezing

    Article • Journal of Allergy and Clinical Immunology, June 2005, Elsevier

    John Williams, Dr James E Crowe

  295. Natural Evolution of a Human Virus-Specific Antibody Gene Repertoire by Somatic Hypermutation Requires Both Hotspot-Directed and Randomly-Directed Processes

    Article • Human Immunology, June 2005, Elsevier

    Dr James E Crowe

  296. Faculty of 1000 evaluation for Stable antibody expression at therapeutic levels using the 2A peptide.

    Article • May 2005, Faculty of 1000, Ltd.

    Dr James E Crowe

  297. Faculty of 1000 evaluation for Serum IgG mediates mucosal immunity against rotavirus infection.

    Article • May 2005, Faculty of 1000, Ltd.

    Dr James E Crowe

  298. Pseudovirion Particle Production by Live Poxvirus Human Immunodeficiency Virus Vaccine Vector Enhances Humoral and Cellular Immune Responses

    Article • Journal of Virology, May 2005, ASM Journals

    Dr James E Crowe

  299. Prevalence of Reovirus‐Specific Antibodies in Young Children in Nashville, Tennessee

    Article • The Journal of Infectious Diseases, April 2005, Oxford University Press (OUP)

    Dr James E Crowe

  300. Application of semiconductor fluorescent nanocrystals as optical probes for rapid early viral detection

    Article • April 2005, SPIE

    Dr James E Crowe

  301. Progression of Respiratory Syncytial Virus Infection Monitored by Fluorescent Quantum Dot Probes

    Article • Nano Letters, April 2005, American Chemical Society (ACS)

    Dr James E Crowe

  302. Differential Regulation of Granzyme and Perforin in Effector and Memory T Cells following Smallpox Immunization

    Article • The Journal of Immunology, March 2005, The American Association of Immunologists

    Dr Thomas R Talbot, Dr James E Crowe

  303. VH1-46 Is the Dominant Immunoglobulin Heavy Chain Gene Segment in Rotavirus-Specific Memory B Cells Expressing the Intestinal Homing Receptor  4 7

    Article • The Journal of Immunology, March 2005, The American Association of Immunologists

    Dr James E Crowe

  304. Smallpox Vaccination Does Not Elevate Systemic Levels of Prothrombotic Proteins Associated with Ischemic Cardiac Events

    Article • The Journal of Infectious Diseases, March 2005, Oxford University Press (OUP)

    Dr James E Crowe, Dr Thomas R Talbot

  305. Faculty of 1000 evaluation for Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease?

    Article • February 2005, Faculty of 1000, Ltd.

    Dr James E Crowe

  306. Cooperativity of actin and microtubule elements during replication of respiratory syncytial virus

    Article • Virology, January 2005, Elsevier

    Dr James E Crowe

  307. Introduction

    Article • The Pediatric Infectious Disease Journal, November 2004, Wolters Kluwer Health

    Dr James E Crowe

  308. Human Metapneumovirus as a Major Cause of Human Respiratory Tract Disease

    Article • The Pediatric Infectious Disease Journal, November 2004, Wolters Kluwer Health

    Dr James E Crowe

  309. Vaccination Success Rate and Reaction Profile With Diluted and Undiluted Smallpox Vaccine

    Article • JAMA, September 2004, American Medical Association (AMA)

    Dr James E Crowe, Dr Thomas R Talbot

  310. Faculty of 1000 evaluation for A role for Streptococcus pneumoniae in virus-associated pneumonia.

    Article • July 2004, Faculty of 1000, Ltd.

    Dr James E Crowe

  311. Faculty of 1000 evaluation for An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.

    Article • July 2004, Faculty of 1000, Ltd.

    Dr James E Crowe

  312. Human Metapneumovirus and Lower Respiratory Tract Disease in Children

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, April 2004, New England Journal of Medicine (NEJM/MMS)

    Dr James E Crowe

  313. Adverse Events after Smallpox Immunizations Are Associated with Alterations in Systemic Cytokine Levels

    Article • The Journal of Infectious Diseases, April 2004, Oxford University Press (OUP)

    Dr James E Crowe, Dr Thomas R Talbot

  314. Effect of Zinc Salts on Respiratory Syncytial Virus Replication

    Article • Antimicrobial Agents and Chemotherapy, March 2004, ASM Journals

    Dr James E Crowe

  315. Faculty of 1000 evaluation for Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120.

    Article • February 2004, Faculty of 1000, Ltd.

    Dr James E Crowe

  316. Human Metapneumovirus and Lower Respiratory Tract Disease in Otherwise Healthy Infants and Children

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, January 2004, New England Journal of Medicine (NEJM/MMS)

    John Williams, Dr James E Crowe

  317. B-Cell Development

    Article • January 2004, Elsevier

    Dr James E Crowe

  318. Apical recycling systems regulate directional budding of respiratory syncytial virus from polarized epithelial cells

    Article • Proceedings of the National Academy of Sciences, November 2003, Proceedings of the National Academy of Sciences

    Dr James E Crowe

  319. Fatal Hemophagocytic Lymphohistiocytosis Associated with Epstein-Barr Virus Infection in a Patient with a Novel Mutation in the Signaling Lymphocytic Activation Molecule--Associated Protein

    Article • Clinical Infectious Diseases, November 2003, Oxford University Press (OUP)

    Dr James E Crowe

  320. Infant and Adult Human B Cell Responses to Rotavirus Share Common Immunodominant Variable Gene Repertoires

    Article • The Journal of Immunology, October 2003, The American Association of Immunologists

    Dr James E Crowe

  321. Faculty of 1000 evaluation for Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.

    Article • July 2003, Faculty of 1000, Ltd.

    Dr James E Crowe

  322. Respiratory Syncytial Virus Nucleoprotein-Specific Cytotoxic T-Cell Epitopes in a South African Population of Diverse HLA Types Are Conserved in Circulating Field Strains

    Article • Journal of Virology, July 2003, ASM Journals

    Dr James E Crowe

  323. Immunology of viral respiratory tract infection in infancy

    Article • Paediatric Respiratory Reviews, June 2003, Elsevier

    Dr James E Crowe

  324. CD154 Regulates Primate Humoral Immunity to Influenza

    Article • American Journal of Transplantation, June 2003, Wiley

    Dr James E Crowe

  325. Planar growth faults in double-layered or triple-layered (Ca,Sr)-ruthenate single crystals by the self-flux technique

    Article • Journal of Crystal Growth, May 2003, Elsevier

    Dr James E Crowe

  326. Faculty of 1000 evaluation for Combinatorial immunoglobulin light chain variability creates sufficient B cell diversity to mount protective antibody responses against pathogen infections.

    Article • April 2003, Faculty of 1000, Ltd.

    Dr James E Crowe

  327. Identification of a novel human leucocyte antigen-A*01-restricted cytotoxic T-lymphocyte epitope in the respiratory syncytial virus fusion protein

    Article • Immunology, April 2003, Wiley

    Dr James E Crowe

  328. Generation of recombinant human monoclonal antibodies to rotavirus from single antigen-specific B cells selected with fluorescent virus-like particles

    Article • Journal of Immunological Methods, April 2003, Elsevier

    Dr James E Crowe

  329. Faculty of 1000 evaluation for Mortality associated with influenza and respiratory syncytial virus in the United States.

    Article • January 2003, Faculty of 1000, Ltd.

    Dr James E Crowe

  330. Faculty of 1000 evaluation for Respiratory syncytial virus-induced activation of nuclear factor-kappaB in the lung involves alveolar macrophages and toll-like receptor 4-dependent pathways.

    Article • November 2002, Faculty of 1000, Ltd.

    Dr James E Crowe

  331. Faculty of 1000 evaluation for A common haplotype of interleukin-4 gene IL4 is associated with severe respiratory syncytial virus disease in Korean children.

    Article • November 2002, Faculty of 1000, Ltd.

    Dr James E Crowe

  332. Faculty of 1000 evaluation for Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing.

    Article • November 2002, Faculty of 1000, Ltd.

    Dr James E Crowe

  333. The Human Polymeric Immunoglobulin Receptor Facilitates Invasion of Epithelial Cells by Streptococcus pneumoniae in a Strain-Specific and Cell Type-Specific Manner

    Article • Infection and Immunity, September 2002, ASM Journals

    Dr James E Crowe

  334. PNEUMOCYSTIS CARINII PNEUMONIA IN A GIRL WITH A MIDBRAIN GLIOMA

    Article • Pediatric Hematology and Oncology, January 2002, Taylor & Francis

    Dr James E Crowe

  335. Influence of Maternal Antibodies on Neonatal Immunization against Respiratory Viruses

    Article • Clinical Infectious Diseases, November 2001, Oxford University Press (OUP)

    Dr James E Crowe

  336. Respiratory syncytial virus vaccine development

    Article • Vaccine, October 2001, Elsevier

    Dr James E Crowe

  337. Passively Acquired Antibodies Suppress Humoral But Not Cell-Mediated Immunity in Mice Immunized with Live Attenuated Respiratory Syncytial Virus Vaccines

    Article • The Journal of Immunology, October 2001, The American Association of Immunologists

    Dr James E Crowe

  338. CD40-Ligand in Primate Cardiac Allograft and Viral Immunity

    Article • Immunologic Research, January 2001, Springer Science + Business Media

    Dr James E Crowe

  339. Genetic and Structural Determinants of Virus Neutralizing Antibodies

    Article • Immunologic Research, January 2001, Springer Science + Business Media

    Dr James E Crowe

  340. Recurrent Achromobacter xylosoxidans Bacteremia Associated with Persistent Lymph Node Infection in a Patient with Hyper-Immunoglobulin M Syndrome

    Article • Clinical Infectious Diseases, November 2000, Oxford University Press (OUP)

    Dr James E Crowe

  341. Recurrent Pneumococcal Arthritis as the Presenting Manifestation of X-Linked Agammaglobulinemia

    Article • Clinical Infectious Diseases, November 2000, Oxford University Press (OUP)

    Dr James E Crowe

  342. Aktuelle Ansätze zur Impfstoffentwicklung gegen Respiratory-Syncytial-Virus (RSV)

    Article • Monatsschrift Kinderheilkunde, November 2000, Springer Science + Business Media

    Dr James E Crowe

  343. Evaluation of a Live, Cold‐Passaged, Temperature‐Sensitive, Respiratory Syncytial Virus Vaccine Candidate in Infancy

    Article • The Journal of Infectious Diseases, November 2000, Oxford University Press (OUP)

    Dr James E Crowe

  344. A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3

    Article • Nature Medicine, January 2000, Nature

    Dr James E Crowe

  345. Passive IgA Monoclonal Antibody Is No More Effective Than IgG at Protecting Mice from Mucosal Challenge with Respiratory Syncytial Virus

    Article • The Journal of Infectious Diseases, October 1999, Oxford University Press (OUP)

    Dr James E Crowe, Dr Yi-Wei Tang

  346. The live attenuated subgroup B respiratory syncytial virus vaccine candidate RSV 2B33F is attenuated and immunogenic in chimpanzees, but exhibits partial loss of the ts phenotype following replication in vivo

    Article • Virus Research, January 1999, Elsevier

    Dr James E Crowe

  347. Monoclonal Antibody-Resistant Mutants Selected with a Respiratory Syncytial Virus-Neutralizing Human Antibody Fab Fragment (Fab 19) Define a Unique Epitope on the Fusion (F) Glycoprotein

    Article • Virology, December 1998, Elsevier

    Dr James E Crowe

  348. Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines

    Article • Vaccine, August 1998, Elsevier

    Dr James E Crowe

  349. Isolation of a Second Recombinant Human Respiratory Syncytial Virus Monoclonal Antibody Fragment (Fab RSVF2–5) that Exhibits Therapeutic Efficacy In Vivo

    Article • The Journal of Infectious Diseases, April 1998, Oxford University Press (OUP)

    Dr James E Crowe

  350. Evaluation of a Live, Attenuated Respiratory Syncytial Virus (RSV)Vaccine Candidate, cpts 248/404, in Infancy • 931

    Article • Pediatric Research, April 1998, Springer Science + Business Media

    Dr James E Crowe

  351. Evaluation of Two Live, Cold‐Passaged, Temperature‐Sensitive Respiratory Syncytial Virus Vaccines in Chimpanzees and in Human Adults, Infants, and Children

    Article • The Journal of Infectious Diseases, December 1997, Oxford University Press (OUP)

    Dr James E Crowe

  352. Nucleotide Sequence Analysis of the Respiratory Syncytial Virus Subgroup A Cold-Passaged (cp) Temperature Sensitive (ts)cpts-248/404 Live Attenuated Virus Vaccine Candidate

    Article • Virology, November 1996, Elsevier

    Dr James E Crowe

  353. The role of antibodies in respiratory viral immunity

    Article • Seminars in Virology, August 1996, Elsevier

    Dr James E Crowe

  354. Live Subgroup B Respiratory Syncytial Virus Vaccines that Are Attenuated, Genetically Stable, and Immunogenic in Rodents and Nonhuman Primates

    Article • The Journal of Infectious Diseases, April 1996, Oxford University Press (OUP)

    Dr James E Crowe

  355. Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene

    Article • Virus Genes, January 1996, Springer Science + Business Media

    Dr James E Crowe

  356. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization

    Article • Vaccine, June 1995, Elsevier

    Dr James E Crowe

  357. A Cold-Passaged, Attenuated Strain of Human Respiratory Syncytial Virus Contains Mutations in the F and L Genes

    Article • Virology, April 1995, Elsevier

    Dr James E Crowe

  358. Isolation and characterization of a highly attenuated respiratory syncytial virus (RSV) vaccine candidate by mutagenesis of the incompletely attenuated RSV A2 ts-1 NG-1 mutant virus

    Article • Vaccine, January 1995, Elsevier

    Dr James E Crowe

  359. Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV) A meeting report of the WHO Programme for Vaccine Development

    Article • Vaccine, January 1995, Elsevier

    Dr James E Crowe

  360. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines

    Article • Virus Research, April 1994, Elsevier

    Dr James E Crowe

  361. Recombinant human respiratory syncytial virus (RSV)monoclonal antibody Fab is effective therapeutically when introduced directlyinto the lungs of RSV-infected mice.

    Article • Proceedings of the National Academy of Sciences, February 1994, Proceedings of the National Academy of Sciences

    Dr James E Crowe

  362. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees

    Article • Vaccine, January 1994, Elsevier

    Dr James E Crowe

  363. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis

    Article • Vaccine, January 1994, Elsevier

    Dr James E Crowe

  364. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV

    Article • Vaccine, January 1993, Elsevier

    Dr James E Crowe

  365. Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity.

    Article • Proceedings of the National Academy of Sciences, November 1992, Proceedings of the National Academy of Sciences

    Dr James E Crowe